Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Rhea-AI Summary
Regentis Biomaterials (NYSE:RGNT) developed a new solvent-free manufacturing process for GelrinC that increases production yield by 400%. The process is already patented in India, China and Israel, with a U.S. patent pending. A commercial launch in Europe is planned later this year; a pivotal FDA study is >50% enrolled.
This change is intended to improve production economics, reduce solvent use and support upcoming commercialization in Europe while U.S. regulatory work continues.
Positive
- Production yield +400% per batch for GelrinC
- Solvent-free process reduces flammable/toxic solvent use
- Patents granted in India, China and Israel
- CE Mark approval in the European Union
- U.S. pivotal FDA study >50% enrolled
Negative
- U.S. patent pending (not yet granted)
- Pivotal FDA study still ongoing (not complete)
News Market Reaction – RGNT
On the day this news was published, RGNT gained 5.88%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $972K to the company's valuation, bringing the market cap to $18M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Healthcare / Medical Instruments & Supplies group appeared in the momentum scan; the -2.9% move looked stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | 2025 earnings update | Neutral | +0.8% | Reported 2025 results with IPO cash, losses, and going concern flag. |
| Feb 19 | CMO appointment | Positive | -2.3% | Named new Chief Medical Officer to steer GelrinC clinical and regulatory path. |
| Feb 17 | EU site expansion | Positive | -10.5% | Expanded European clinical network to support GelrinC launch and programs. |
| Feb 04 | CFO/CBO hire | Positive | -0.2% | Appointed new CFO/CBO as GelrinC advanced toward EU launch and U.S. trial. |
| Jan 29 | U.S. site expansion | Positive | -4.8% | Added U.S. orthopedic centers to accelerate Phase III GelrinC enrollment. |
Recent operational and clinical updates have frequently been followed by negative or muted price reactions, even when the news skewed positive.
Over the last few months, Regentis has focused on advancing GelrinC toward commercialization. Updates included U.S. and European site expansions, leadership additions in finance and medical roles, and 2025 earnings that combined a $10.0 million IPO and $7.4 million cash with a going concern warning. Despite generally constructive clinical and commercial milestones, four of the last five news days showed negative price reactions. Today’s manufacturing-process improvement fits into this commercialization build‑out around GelrinC’s CE-marked knee cartilage repair indication and ongoing pivotal FDA trial.
Market Pulse Summary
The stock moved +5.9% in the session following this news. A strong positive reaction aligns with the operational significance of a solvent-free process that boosts GelrinC production yield by 400%. Historically, however, RGNT’s stock sometimes reacted weakly to positive commercialization updates, so a large upside move would stand out. Investors would likely weigh this manufacturing leverage against past disclosures of losses and going concern risk, monitoring future capital raises and execution of the upcoming European launch and ongoing pivotal FDA trial.
Key Terms
hydrogel medical
organic solvents technical
ce mark regulatory
u.s. food and drug administration regulatory
AI-generated analysis. Not financial advice.
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year
Proprietary process is already patented in several countries and is pending in the U.S.
HERZLIYA, IL / ACCESS Newswire / March 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced it has developed a new manufacturing process for its lead product, GelrinC®, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. The proprietary new process does not require the use of organic solvents which are not only flammable and toxic but also take up a major portion of the manufacturing process volume. This new solvent-free process more than quadruples production yield per batch.
"In preparation for GelrinC's commercial launch in Europe, planned for later this year, we have been developing and patenting proprietary improvements to our GelrinC manufacturing process that will improve production economics and corresponding gross margins," said Dr. Ehud Geller, CEO and Executive Chairman of Regentis.
Regentis has filed patents worldwide for its solvent-free GelrinC manufacturing process that have already been granted in India, China and Israel, and is pending in the US.
GelrinC has CE Mark approval in the European Union and Regentis is conducting a pivotal U.S. Food and Drug Administration study which has completed over
About GelrinC®
Regentis' lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC® offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 5 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC® has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
Forward Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding Regentis' advancement towards commercialization and its cash runway. Forward-looking statements are based on Regentis' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the section titled "Risk Factors" in our Annual Report on Form 20-F filed with the SEC on February 24, 2026 and other public reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.
Contact:
SOURCE: Regentis Biomaterials Ltd
View the original press release on ACCESS Newswire
FAQ
What does Regentis' new solvent-free process mean for RGNT production yield?
Where has Regentis patented the GelrinC solvent-free process for RGNT?
When is RGNT planning the GelrinC commercial launch in Europe?
How does the new process affect GelrinC safety and manufacturing operations for RGNT?
What is the regulatory status of GelrinC for RGNT in the EU and U.S.?
Will the new manufacturing process improve RGNT gross margins?
